NRG1 and hyperinsulinemic hypoglycemia, familial, 4: The NCCN suggests that testing for actionable somatic findings with fusions [Anaplastic lymphoma kinase (ALK), Neuregulin-1 gene (NRG1), NTRK, ROS proto-oncogene 1 (ROS1)], mutations [Proto-oncogene B-Raf (BRAF), BRCA1/2, Human epidermal growth factor receptor 2 (HER2), Kirsten rat sarcoma viral oncogene homologue (KRAS), Partner and Localizer of BRCA2 (PALB2)], and MMR deficiency must be considered in metastatic or locally advanced, unresectable disease (2).